ABSTRACT Therapeutic temperature management (TTM) was strongly recommended by the 2015 International Liaison Committee on Resuscitation as a component of post-resuscitation care. It has been known to be effective in improving the survival rate and neurologic functional outcome of patients after cardiac arrest. In an effort to increase local adoption of TTM as a standard of post-resuscitation care, this paper discusses and makes recommendations on the treatment for local providers.
INTRODUCTION
There has been increasing awareness in the community of the need to improve out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA) survival in Singapore. Numerous factors can impact survival and these may be organised according to the chain of survival concept, which includes early access, early cardiopulmonary resuscitation (CPR), early defi brillation, early advanced care and post-resuscitation care.
(1) Despite CPR and defi brillation, a large proportion of the victims who survive to hospital admission still die.
Therapeutic hypothermia or therapeutic temperature management (TTM) and its potential benefi ts have been known for a few decades, but only gained wide support after two landmark studies were published in 2002. These studies showed signifi cant improvement in both survival and neurological outcomes for post-cardiac arrest patients. (2, 3) By cooling the patient's body after resuscitation, reperfusion injury due to infl ammation and free radical production is suppressed, thereby reducing cell death and injury to the brain and vital organs. (4) The use of TTM is strongly recommended in the 2015 update by the International Liaison Committee on Resuscitation for patients with ventricular fi brillation (VF) or pulseless ventricular tachycardia (pVT). (5) Although TTM is a recommended standard of care, its adoption in Singapore for cardiac arrest patients is not widespread. The local awareness and understanding of its science and evidence, as well as experience in its implementation, remain limited.
PATHOPHYSIOLOGY AND EFFECTS OF TTM
After resuscitation from cardiac arrest, a complex series of processes occurs within minutes to hours, leading to cellular level injury. Cerebral ischaemic damage happens within seconds when cerebral circulation is compromised. Glucose and adenosine triphosphate are depleted, and cells begin to lose structural integrity, leading to mitochondrial damage and loss of calcium homeostasis. Cerebral reperfusion injury occurs when the restoration of oxygenation leads to the accumulation of oxygen free radicals and activation of degradative enzymes. (3, 4, 6) Therapeutic hypothermia reduces the release of excitatory amino acids, free radicals and the intracellular consequences of excitotoxin exposure. (6) It also decreases the cerebral metabolic rate by 6% for every 1°C drop in core body temperature, thus reducing cerebral oxygen demand. 
RECOMMENDATIONS

Indications for TTM
TTM is recommended for all patients with return of spontaneous circulation (ROSC) from cardiac arrest who have abnormal conscious levels during the immediate post-arrest period.
Cooling to mild hypothermia temperatures has been shown to have survival and neurological benefi ts for cardiac arrest patients with shockable rhythms. Two randomised controlled trials (RCTs) provided clear evidence that TTM should be used for patients with shockable rhythms. (2, 3) A decrease in mortality and improvement in neurological outcome were shown in patients presenting with ventricular tachycardia (VT) and pVT rhythms, who remained comatose after ROSC and received TTM. (2, 3) In these studies, 49%-55% of patients who received some form of TTM survived with favourable neurological outcome, compared to the 26%-39% of patients who did not receive TTM.
Therapeutic temperature management (TTM):
Therapeutic temperature management (TTM): post-resuscitation care for adult cardiac arrest, with post-resuscitation care for adult cardiac arrest, with recommendations from the National TTM Workgroup recommendations from the National TTM Workgroup
For patients presenting with nonshockable rhythms or IHCA, the evidence is less consistent. (5, 8) A meta-analysis by Kim et al (9) found that TTM was benefi cial for cases of nonshockable rhythms, although the included studies had substantial risk for bias. Although the level of evidence is low, TTM remains recommended for these patients.
Target temperature for TTM
A target temperature of 33°C-36°C should be selected and maintained within a 1°C variation for the duration of TTM. For patients with OHCA due to shockable rhythms, a lower target temperature of 33°C is recommended. If contraindications to lower temperatures are present, a higher target temperature of 36°C may be used. Fever should be prevented in all patients with cardiac arrest and abnormal consciousness levels, and thus 36°C should be the minimum target temperature of cooling for all patients. Early studies have attempted the use of deep hypothermia of below 30°C to provide neurological protection. Deep hypothermia (below 25°C-28°C) was suggested purely with the assumption that hypothermia induced lower metabolism. It was later found in animal studies that mild hypothermia provided signifi cant protective effects with much fewer side effects.
Since the two RCTs in 2002, (2, 3) the target temperature of 32°C-34°C has been adopted as the recommended target. (2, 3, 5, 8) A subsequent RCT, which compared the target temperatures of 33°C vs. 36°C for cardiac arrests of all rhythms, found no difference in outcomes. (10) In the Nielsen et al study, both the intervention and the control groups were given some form of TTM. The only difference was the target temperature. (10) This was in contrast to the studies by the Hypothermia after Cardiac Arrest study group (2) and Bernard et al, (3) where only the intervention groups received TTM; the control groups were reported to have temperatures averaging 38°C. In light of the original evidence that TTM at a target temperature of 32°C-34°C has been proven to be superior to no TTM for shockable rhythms, a lower target temperature of 33°C remains recommended for this group. However, in the presence of contraindications such as sepsis, coagulopathy and cardiac dysrhythmias, a higher target of 36°C is acceptable. For patients with nonshockable rhythms or IHCA, a temperature target of 36°C is acceptable. Fever in the post-arrest period has been associated with poorer outcomes (11, 12) and should be avoided in all groups.
Duration of TTM and rewarming
TTM should be induced and maintained at the selected target temperature for 24 hours, and rewarmed gradually at a rate not faster than 0.5°C per hour. Every hour of delay in TTM after ROSC increases mortality by 20%. Thus, TTM should be initiated as soon as possible after ROSC. While there is low-quality evidence regarding the duration of cooling, most studies have suggested that rewarming should begin 24 hours after the patient has reached the target temperature. (6, 8) Patients should not be rewarmed rapidly, as rapid rewarming has been associated with complications, including hypotension, electrolyte changes and dysrhythmias. It is recommended that rewarming should occur at a rate not faster than 0.5°C every hour until normothermia.
COMPLICATIONS OF TTM Cardiovascular
There may be a decrease in cardiac output by 25%-40% due to a decrease in heart rate during hypothermia. The central venous pressure, arterial resistance and blood pressure may rise due to vasoconstriction of peripheral arteries and arterioles induced by hypothermia. (13, 14) Bradycardia is the most common arrhythmia when cooling begins. However, temperatures below 30°C are associated with increased risk of atrial fi brillation, VF and asystole. Bradycardia should be treated if it is associated with hypotension. (6) Hypotension is common during rewarming. During cooling, cold diuresis and vasoconstriction result in a reduction of intravascular volumes. When the patient is rewarmed, vasodilation from reversal of vasoconstriction and post-resuscitation infl ammatory release, as well as reduced intravascular volume, increase the risk of hypotension. Direct cardiac dysfunction from the initial ischaemic insult may also worsen hypotension. In the absence of cardiac or renal failure, fl uid replacement should be initiated to mitigate hypotension, and to avoid cerebral hypotension and recurrent hypoperfusion.
Shivering
Shivering is a common refl ex to cooling and typically occurs during changes in temperature of between 35°C and 37°C. Once a patient achieves the target temperature of 32°C-34°C, shivering is less common. (6) It should be recognised and controlled early, as it increases metabolic demand and prevents or delays achievement of target temperatures. Sedation and analgesia help to reduce shivering. Paralytic agents may also be needed to suppress the shivering refl ex. If used, they must be given together with sedative and analgesic agents to avoid patient awareness during the paralysis, which may be extremely distressing. Neurological monitoring during paralysis is also essential. This may include the use of continuous electroencephalogram to detect conscious level changes and nonconvulsive seizures. Warming of the peripheries (e.g. using mittens, stockings, hot packs, blankets on the hands/ feet) may also help to reduce shivering.
Infections
Hypothermia impairs neutrophil and macrophage function, and suppresses infl ammatory mediators. (15, 16) Owing to the active cooling process, recognition of fever is not possible. Pneumonia and sepsis have been found to be increased during hypothermia. (17) Therefore, care must be taken to monitor and treat infections.
Endocrine effects
Hypothermia decreases insulin secretion and increases insulin resistance, causing hyperglycaemia in patients receiving TTM. The glucose level of patients can fall precipitously during rewarming. Blood glucose should thus be monitored regularly and actively managed.
Renal
Owing to fluid and electrolyte shifts during cooling and rewarming, electrolyte levels may change signifi cantly. Potassium levels may fall from diuresis or cellular shifts during cooling, and potassium may shift back into the bloodstream during rewarming. Patients with renal failure may need to be dialysed prior to rewarming. Calcium, magnesium and phosphate levels may also be affected. Therefore, close monitoring of electrolytes during TTM is crucial.
Gastrointestinal
Gastrointestinal motility is reduced during TTM and there may be an increased likelihood of stress ulcers. Liver and pancreatitic dysfunction such as raised transaminases and amylase may occur.
Haematological
Platelet counts, platelet function and other clotting factors of the patient can be affected by hypothermia, and this may induce mild bleeding diathesis. (14) The effect will not show in standard coagulation tests unless they are performed at the patient's actual core temperature. While no clinically signifi cant bleeding has been reported in large clinical trials, the benefi t to neurological function should be assessed against the severity and location of bleeding. (8) 
Pharmacological
Drug metabolism is impaired during hypothermia owing to reduced hepatic clearance, and the effects may be prolonged.
Hyperthermia
Fever is a common complication in patients with various types of neurological injury. It should be prevented for at least 72 hours after rewarming. Hyperthermia is harmful and leads to a worse neurological outcome.
Peripheral complications
Direct cold injury (depending on the cooling device used) and peripheral vasoconstriction can lead to skin necrosis, gangrene of digits/limbs and infections. Good skin care and monitoring is important.
LOCAL EVIDENCE FOR TTM
A local study showed that survival to discharge trended higher in patients who underwent TTM (TTM 44.0% vs. control 16.0%; p = 0.06). (18) Survivors in the intervention group had good neurological recovery (Cerebral Performance Category 1/2: 63.6%; Overall Performance Category 1/2: 54.5%). Patients who were cooled using external methods (cooling pads) compared to internal methods (cooling catheters) appeared to be more likely to have both overcooling (internal 33.3% vs. external 50.0%) and undercooling (internal 88.9% vs. external 93.8%). Rebound hyperthermia (defi ned as temperature overshoot ≥ 38.0°C) was observed in only 4 (16.0%) patients, all of whom were on external cooling. (18) TTM has also been incorporated into local protocols for extracorporeal membrane oxygenation and acute percutaneous coronary intervention.
CONCLUSION
TTM is an important component in post-resuscitation care. Evidence has shown that mild hypothermia is effective in improving the neurological function of patients who remain comatose post-ROSC. TTM is recommended for all post-ROSC patients regardless of initial shockable or nonshockable rhythm, as well as in both OHCA and IHCA.
